Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Anifat A. Elegbede, MSc"'
Autor:
Anifat A. Elegbede, MSc, MbChB, Amanda J. Gibson, BSc, Andrea S. Fung, PhD, MD, Winson Y. Cheung, MD, MPH, Michelle L. Dean, BSc, D. Gwyn Bebb, BMBCh, PhD, Aliyah Pabani, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 12, Pp 100249- (2021)
Introduction: The real-world data evaluating treatment outcomes of atezolizumab plus carboplatin-etoposide chemotherapy (atezolizumab) for extensive-stage SCLC (ESCLC) are lacking. Our objective was to evaluate real-world outcomes of ESCLC treated wi
Externí odkaz:
https://doaj.org/article/6d9518960e1846f9a1d2a211e151b458
Autor:
Amanda J.W. Gibson, BSc (Hons), Adrian Box, MD, PhD, Michelle L. Dean, BSc, Anifat A. Elegbede, MSc, Desiree Hao, MD, Randeep Sangha, MD, D. Gwyn Bebb, BMBCh, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 4, Pp 100157- (2021)
Introduction: This study explored the use, safety, and efficacy of initial use of an ALK-inhibiting targeted therapy (ALK tyrosine kinase inhibitor [TKI]) in patients with ALK-rearranged NSCLC in a population-based, real-world clinical population wit
Externí odkaz:
https://doaj.org/article/7caa4c9d3fd2409c996385d60ce3c991